[ACX 2026] Will the US, UK or EU approve a gene editing therapy for a new condition during 2026?
EuropaOne-OffGezondheid en geneeskundeWetenschap2mndManifold MarketsGeen KYCGeverifieerde afwikkelingsgegevensRedelijk gekalibreerdHuidige gemeenschapsvoorspellingNee 90.2%
Voorspellers
29
Vraagtype
binary
Methodologie
Play-money forecasting platform
Brontype
Voorspelling
Marktdata
Bijgewerkt 6 uur geleden
Verouderd6 jan 26, 22:51 UTC31 dec 26, 23:59 UTC
Trends
Gerelateerde Markten
Gerelateerde vragen voor context, geen vergelijking van gelijkwaardige contracten.
When will commercial gene-editing therapy be available?
Manifold MarketsWill a CRISPR-based gene editing therapy for transthyretin (ATTR) amyloidosis be available in the US by 2027?
Manifold MarketsBy 2030, will gene editing to cure serious genetic diseases be seen as generally uncontroversial?
Manifold MarketsWill GiveWell research gene-editing mosquitoes to eradicate malaria?
Manifold MarketsThere will be more children born via artificial wombs than not in first world countries before 2050
Manifold MarketsPreimplantation genetic diagnosis liberalised in Germany before 2027?
Manifold MarketsRegels
(https://www.metaculus.com/questions/embed/41169) Resolves according to Metaculus resolution.
- Metaculus high-level description: This question will resolve as Yes if any of the US FDA, UK MHRA, or the EU Commission authorizes the use or sale of a therapy whose primary mechanism directly editing the patient's genomic DNA for any human condition other than sickle cell disease and beta thalassemia before January 1, 2027.
